Sugi Predict

Sugi Predict / Compounds / SCHEMBL564213

SCHEMBL564213

SCHEMBL564213

O=C(CCl)C1=NOC(c2c(F)cccc2F)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.35
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ MEN1 O00255 4/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ LMNA P02545 3/20 0.32
▸ MAPT P10636 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ TRPA1 O75762 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19525864 0.86 POLB (0.35) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL192955 0.86 POLB (0.35) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL10163553 0.86 POLB (0.35) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL24941709 0.84 IDO1 (0.31) ALDH1A1LMNAMAPTHPGDGAA
SCHEMBL19525865 0.81 POLB (0.38) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL193085 0.81 POLB (0.38) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL1979983 0.78 TSHR (0.47) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL19525866 0.78 POLB (0.37) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL192351 0.78 POLB (0.37) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL3665372 0.75 PPARG (0.35) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604495-B2 Process for preparing substituted phenylisoxazoline derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-03-31 — — US disclosed
WO-2020034992-A1 FUSED HETEROCYCLE STRUCTURE-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATIONS THEREOF, AND FUNGICIDE 华中师范大学 2020-02-20 — — WO disclosed
EP-3265446-B1 PROCESS FOR PREPARING SUBSTITUTED PHENYLISOXAZOLINE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2019-08-14 — — EP disclosed
US-10189799-B2 Process for preparing substituted phenylisoxazoline derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-01-29 — — US disclosed
US-20190016691-A1 PROCESS FOR PREPARING SUBSTITUTED PHENYLISOXAZOLINE DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2019-01-17 — — US disclosed
US-20180030002-A1 Process for preparing substituted phenylisoxazoline derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-02-01 — — US disclosed
US-20180030002-A1 Process for preparing substituted phenylisoxazoline derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-02-01 — — US disclosed
US-9062040-B2 Solid forms of an azocyclic amide E I DU PONT DE NEMOURS AND COMPANY (US) 2015-06-23 — — US disclosed
EP-2521450-B1 FUNGICIDAL HETEROCYCLIC COMPOUNDS DU PONT (US) 2015-02-25 — — EP disclosed
US-20150031541-A1 MICROBIOCIDAL PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-29 — — US disclosed
US-20140127322-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE E I DU PONT DE NEMOURS AND COMPANY (US) 2014-05-08 — — US disclosed
US-8669277-B2 Solid forms of an azocyclic amide E I DU PONT DE NEMOURS AND COMPANY (US) 2014-03-11 — — US disclosed
WO-2013127808-A1 MICROBIOCIDAL PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2013-09-06 — — WO disclosed
EP-2421861-B1 SOLID FORMS OF AN AZOCYCLIC AMIDE DU PONT (US) 2013-01-16 — — EP disclosed
US-20120309752-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS E I DU PONT DE NEMOURS AND COMPANY (US) 2012-12-06 — — US disclosed
EP-2521450-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS E.I. Du Pont De Nemours And Company (US) 2012-11-14 — — EP disclosed
EP-2421861-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE E. I. du Pont de Nemours and Company (US) 2012-02-29 — — EP disclosed
US-20120034315-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-02-09 — — US disclosed
WO-2011085170-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2011-07-14 — — WO disclosed
WO-2010123791-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189799-B2 Process for preparing substituted phenylisoxazoline derivatives CYP3A7, CYP3A4, CYP4X1 POLB 1028/4885NPC1 2178/4885RAB9A 3725/4885
US-20140127322-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE NOD1, NUAK1, DDT POLB 3860/4885NPC1 285/4885RAB9A 2573/4885
US-10604495-B2 Process for preparing substituted phenylisoxazoline derivatives CYP3A7, CYP3A4, CYP4X1 POLB 1028/4885NPC1 2178/4885RAB9A 3725/4885
US-20190016691-A1 PROCESS FOR PREPARING SUBSTITUTED PHENYLISOXAZOLINE DERIVATIVES CYP3A7, CYP3A4, CYP4X1 POLB 1028/4885NPC1 2178/4885RAB9A 3725/4885
US-20120309752-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS CYP1B1, NOX3, CYP1A1 POLB 4536/4885NPC1 649/4885RAB9A 1177/4885
US-20180030002-A1 Process for preparing substituted phenylisoxazoline derivatives CYP3A7, CYP3A4, CYP4X1 POLB 1028/4885NPC1 2178/4885RAB9A 3725/4885
US-20120034315-A1 SOLID FORMS OF AN AZOCYCLIC AMIDE NOD1, NUAK1, DDT POLB 3860/4885NPC1 285/4885RAB9A 2573/4885
US-20150031541-A1 MICROBIOCIDAL PYRAZOLE DERIVATIVES PRF1, CASP1, MPO POLB 2555/4885NPC1 1109/4885RAB9A 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.